卵巢癌腹腔积液中ERCC1表达与铂剂相关性研究

Studies on Correlation between ERCC1 Expression and Platinum in Ovarian Carcinoma Ascites

目的探讨卵巢癌恶性腹腔积液中ERCC1表达水平与铂类药物化疗疗效及预后关系。方法存在恶性腹腔积液的晚期卵巢癌患者腹水标本65例,采用流式细胞术检测腹水肿瘤细胞ERCC1蛋白表达水平。Kaplan Meier生存曲线分析比较不同ERCC1表达水平患者的中位生存期和无病进展时间。结果 ERCC1的阳性率为38.5%。ERCC1低表达者含铂方案化疗效果优于高表达者,但两者间的差异无统计学意义(P>0.05);ERCC1低表达的患者总生存期(overall survival,OS)明显长于高表达者(P=0.03)。结论腹腔积液中肿瘤细胞ERCC1表达与卵巢癌预后具有相关性,与铂剂化疗疗效的关系尚待进一步明确。

Objective To investigate the expression of excision repair cross complementation group 1 (ERCC1)in ovarian carcinoma ascites and explore the correlation of ERCC1 expression with therapeutic effect of cisplatin and survival time.Methods Ascites were collected from 65 patients from March 2012 to March 2014 at the Fourth Hospital of Hebei Medical University,while the expression of ERCC1 protein was studied by immuno-cytochemistry staining,and Kaplan Meier survival curve analysis was used to compare median overall survival time and median progression free survival time among the patients of with different expression of ERCC1.Results The positive rates of ERCC1 expression in ovarian Carcinoma samples were 38.5%,while the therapeutic effect of cis-platin in patient with ERCC1 low expression was obviously better than that with ERCC1 high expression (P>0.05).The median overall survival time and progression free survival time of patients with ERCC1 low ex-pression were obviously longer than that with high expression (P=0.03).Conclusions The ERCC1 expression in ascites could correlate with prognosis in ovarian carcinoma.